Volume 26, Number 1—January 2020
Research Letter
Hantavirus Pulmonary Syndrome in Traveler Returning from Nepal to Spain
Table
Findings | Acute phase, day 2 | ICU admission, day 6 | ICU discharge, day 12 | Follow-up, day 22 | Follow-up, day 82 |
---|---|---|---|---|---|
Clinical |
Fever, myalgia, headache, vomiting, and diarrhea |
Acute noncardiac pulmonary edema and hypotension; pleural effusions and respiratory failure |
Eupneic, resolution of the pulmonary edema |
Mild dyspnea general condition with fatigue |
Completely recovered |
Hematalogic |
Leukocytes 4.38 × 109 cells/L; platelets 125 × 109/L |
Leukocytes 6.17 × 109 cells/L; platelets 92 × 109/L |
Leukocytes 7.00 × 109 cells/L; platelets 306 × 109/L |
Leukocytes 4.91 × 109 cells/L; platelets 205 × 109/L |
Leukocytes 5.82 × 109 cells/L; platelets 208 × 109/L |
Biochemical |
AST 81 IU/L; ALT 127 IU/L; ALP 142 IU/L; GGT 128 IU/L; creatinine 1.02 g/dL; urea 37 mg/dL; Na+ 140 mmol/L; K+ 4.24 mmol/L; cholesterol 113 mg/dL; triglycerides 78 mg/dL; CRP 10.33 |
AST 448 IU/L; ALT 424 IU/L; ALP 151 IU/L; GGT 150 IU/L; cardiac biomarkers (troponin and natriuretic peptide) normal; creatinine 0.86 mg/dL; urea 53 mg/dL; Na+ 135.6 mmol/L; K+ 4.39 mmol/L; LDH 830 UI/L; CRP 14.58 |
AST 117 IU/L; ALT 205 IU/L; Creatinine 0.56 mg/dL; Urea 28 mg/dL; Na+ 141.8 mmol/L; K+ 4.38 mmol/L; cholesterol 121 mg/dL; triglycerides 218 mg/dL; CRP 2.81 |
AST 46 IU/L; ALT 106 IU/L; ALP 176 IU/L; GGT 143 IU/L; creatinine 0.71 mg/dL; Urea 30 mg/dL; Na+ 139.5 mmol/L; K+ 4.58 mmol/L |
AST 24 IU/L; ALT 19 IU/L; GGT 12 IU/L; creatinine 0.95 mg/dL; urea 33 mg/dL; Na+ 140.2 mmol/L; K+ 4.78 mmol/L |
Arterial blood gas analysis |
NA |
pH 7.36; PaCO2 32 mm Hg; PaO2 40 mm Hg; SaO2 85.5%; HCO3- 26.3 mm Hg |
NA |
NA |
NA |
Pleural effusion characteristics |
NA |
Glucose 114 mg/dL; proteins 2.1 g/dL; LDH 423 IU/L; cytology inflammatory process with lymphocyte predominance |
NA |
NA |
NA |
Hantavirus diagnosis | IgG (ELISA) negative; IgG (IBT) negative; IgM (ELISA) negative; IgM (IBT) negative; PCR (serum + urine) negative | NA | IgG (ELISA) weak positive; IgG (IBT) positive, PUUV indeterminate, Dobrava Seoul, Hantaan, Sin Nombre and Andes negative; IgM (ELISA) indeterminate; IgM (IBT) negative; PCR (serum) negative; DENV IgG, IgM negative, PCR (serum) negative | IgG (ELISA) positive; IgG (IBT) positive; PUUV indeterminate; Dobrava, Sin Nombre and Andes and negative Seoul and Hantaan; IgM (ELISA) positive; IgM (IBT) negative; PCR (serum) negative | IgG (ELISA) indeterminate; IgG (IBT) indeterminate; PUUV, Dobrava, and Seoul negative Hantaan, Sin Nombre and Andes; IgM (ELISA) negative; IgM (IBT) negative; PCR (serum) negative |
*Days are days after initial symptom onset. An expanded table including additional results is available (https://wwwnc.cdc.gov/EID/article/26/1/18-1685-T1.htm). ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; DENV, dengue virus; GGT, gamma-glutamyl transpeptidase; IBT, immunoblot; ICU, intensive care unit; LDH, lactate dehydrogenase; NA, not applicable; PUUV, Puumala virus.
1These authors contributed equally to this article.
Page created: December 18, 2019
Page updated: December 18, 2019
Page reviewed: December 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.